NCT00063154View on ClinicalTrials.gov

Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Pertuzumab

Pertuzumab was supplied as a single-use liquid formulation.

Trial Locations (8)

85258

Arizona Cancer Center, Scottsdale

90048

Cedars-Sinai Comprehensive Cancer Center, Los Angeles

95817

University of California Davis Cancer Center, Sacramento

85724-5024

Arizona Cancer Center, Tucson

02115

Dana Farber Cancer Institute, Boston

10021-6007

Memorial-Sloan Kettering Cancer Center, New York

37232-5536

Vanderbilt Ingram Cancer Center, Nashville

77030-4009

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY